Tagged with BIO

China The latest reporting on China biopharma dealmaking from MSQ Ventures, including the Top 10 biotech in-licensing deals in H1 2021, the Top 5 out-licensing deals, and Top 10 IPOs.   Made with Visme Infographic Maker Made with Visme Infographic Maker Made with Visme Infographic Maker

Denmark Long established as a premier early launch country for innovative medicines within Europe, the Danish market access system has become more complicated of late as the Danish Medicines Council – the body charged with providing guidance about new medicines for use in the Danish hospital sector – adjusts to the…

Denmark Tore von Würden talks through Amgen Denmark’s focus areas of osteoporosis, cardiovascular disease, haematology, and oncology, where it hopes not only to provide medicines but also contribute to the overall ecosystem. von Würden also explains the logic and relevance of the company’s M&A activity in Denmark in recent years, highlights…

Denmark Tashia Lentz of Biogen outlines what she sees as an increasingly tough market access environment for new treatments in Denmark and calls for greater stakeholder openness to innovative pricing schemes. Lentz also makes a comparison between the life sciences ecosystems in Sweden, where she spent three years heading up Astellas’…

Sweden Anders Blanck, CEO of Lif, the trade association for the research-based Swedish pharmaceutical industry, writes about the challenges the world faces from antimicrobial resistance (AMR). Sweden has for decades been a pioneer in the field, and Blanck believes that Sweden is an excellent test market for various incentive models that,…

Turkey Best known as the company that launched the world’s first “antibody biosimilar,” Celltrion is looking to continue its growth as a global biopharmaceutical company. Its general manager for Turkey, SeokHoon Kang and commercial director, Mahmut Uyar, outline the Korean company’s strong performance in 2020, how they are leveraging their commercial…

Saudi Arabia Biologix is a Dubai-based firm that represents international pharma companies by bringing innovative drugs to market in the Middle East / North Africa (MENA) region. Its GM, Zeina Sfeir Lahoud, discusses the company’s presence in over 17 countries, their 25 years of experience in Saudi Arabia, and the dynamics shaping…

Turkey Polifarma is a Turkish pharma company dedicated to the hospital sector and biosimilars. Its chairman, Ufuk Kumrulu, explains how the company has managed to become a top two company in the hospital segment after Roche, discusses their big bet on biosimilar products through an R&D center and manufacturing plant, and…

Italy An overview of Italy’s pharma, biotech and medtech sectors by number of companies, production value, R&D investment, and number of employees. Made with Visme Infographic Maker   The Italian companies involved in healthcare, split by specialisation, R&D spend, and turnover Made with Visme Infographic Maker   Italy’s regions and their…

Turkey Drawing on over a dozen interviews with C-level pharmaceutical industry executives in Turkey, PharmaBoardroom has compiled a strategic overview of Turkey’s pharma talent potential, including what local talent can offer to global organisations, why the well-educated and cost-efficient domestic labour force is so important to the Turkish pharma market’s future,…

USA In his latest PharmaBoardroom piece, John Singer looks at Biogen’s marketing campaign for its new Alzheimer’s drug, extending and linking the controversy to the grander strategic themes reshaping the ‘drug market’ as a whole, including the impact of the internet on cognitive change, the unmet need for a different premise for…

Switzerland Dr Vincent Forster of Versantis, a Swiss biotech aiming to develop a new generation of liver disease therapeutics and diagnostics, introduces the company’s foundation story, proprietary technology, and future development goals.   As a start-up company, we try to work in a very lean and dynamic way with a small…